Food-derived bioactive peptides demonstrate the ability to modulate gut microbiota composition, which subsequently influences muscle metabolism and function through the emerging gut-muscle axis. These natural compounds represent a novel therapeutic pathway for addressing sarcopenia, the progressive muscle wasting that affects aging populations worldwide. The gut-muscle connection operates through multiple mechanisms: beneficial bacteria produce metabolites like short-chain fatty acids that support muscle protein synthesis, while peptides can selectively promote growth of muscle-supporting microbes and suppress inflammation-inducing species. This approach offers significant advantages over traditional interventions by targeting the root cause rather than symptoms. However, substantial research gaps remain. Current evidence relies heavily on animal models with questionable human translation, while detection methods lack precision for tracking peptide-microbiota interactions. Most critically, clinical validation is virtually absent. The field needs rigorous human trials to establish efficacy and optimal dosing. Despite these limitations, the gut-muscle axis represents a paradigm shift in sarcopenia prevention, potentially offering a food-based solution to one of aging's most debilitating conditions.